EUVIMEDEUVIMED entdecken
Crossref

Cholinergic drugs reduce metabolic inflammation and diabetic myocardial injury by regulating the gut bacterial component lipopolysaccharide‐induced ERK /Egr‐1 pathway

Qing Wu, Ming Zhao, Dongling Li, Xi He, Weijin Zang iD

The FASEB Journal · 2023

DOI: 10.1096/fj.202202108r ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Qing Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, P.R. China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Endotoxemia, Diabetic Cardiomyopathies, Diabetes Mellitus. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autonomic imbalance and metabolic inflammation are important pathological processes in diabetic cardiomyopathy. Gut microbiota dysbiosis and increased levels of bacterial component lipopolysaccharide (LPS) are associated with diabetic myocardial injury, but the mechanism by which gut microbes affect metabolic inflammation and cardiac injury remains unclear. We determined whether pyridostigmine (PYR), which inhibits cholinesterase to improve vagal activity, could regulate the disordered gut microbiota and attenuate gut barrier dysfunction, metabolic endotoxemia, and inflammation in diabetes. Db/db mice exhibited high blood glucose levels, insulin resistance, low vagal activity, and diabetic myocardial injury. Db/db mice also exhibited gut microbiota perturbations and subsequent disruption of gut barrier function, resulting in an influx of LPS, metabolic endotoxemia, and inflammation. PYR ameliorated the dysregulated glucose and lipid metabolism, modulated the overall structure of the gut microbiota, selectively enhanced the abundance of anti‐inflammatory bacteria, and reduced the abundance of proinflammatory and potentially pathogenic bacteria in db/db mice. Importantly, PYR enhanced vagal activity, restored gut microbiota homeostasis, and alleviated gut barrier dysfunction. Therefore, the LPS‐induced extracellular signal‐regulated kinase (ERK)/early growth response‐1 (Egr‐1) pathway and consequent metabolic inflammation were inhibited, and eventually, cardiac hypertrophy, fibrosis, oxidative stress, and dysfunction were ameliorated in db/db mice. In vitro cardiomyocyte injury was induced by exposing primary neonatal rat ventricular cardiomyocytes to high glucose (HG) and LPS. In vitro analyses showed that HG + LPS induced ERK1/2 phosphorylation, Egr‐1 expression, inflammation, and cell apoptosis, which were inhibited by acetylcholine (ACh). Alpha 7 nicotinic ACh receptor but not muscarinic 2 ACh receptor plays an important role in ACh‐mediated anti‐inflammatory effects and inhibiting the ERK/Egr‐1 pathway in HG + LPS‐administered neonatal rat ventricular cardiomyocytes. PYR and ACh ameliorated diabetic myocardial injury by inhibiting the LPS‐induced ERK/Egr‐1 pathway and metabolic inflammation. The vagus–gut–heart axis has provided new insights into the complex mechanisms of diabetes and offers novel therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeEndotoxemiaDiabetic CardiomyopathiesDiabetes MellitusMiceRatsAnimalsLipopolysaccharidesExtracellular Signal-Regulated MAP KinasesInflammationAnti-Inflammatory AgentsAcetylcholineCholinergic AgentsBacteriaGlucoseReceptors, Cholinergic

Stichwörter der Autor:innen

ERK/Egr-1 pathwaycholinergic drugsdiabetic myocardial injurygut microbiotalipopolysaccharidemetabolic inflammation

Substanzen

LipopolysaccharidesExtracellular Signal-Regulated MAP KinasesAnti-Inflammatory AgentsAcetylcholineCholinergic AgentsGlucoseReceptors, Cholinergic

Autor:innen und Institutionen

  • Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, P.R. China.

ORCID-Profile: Weijin Zang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, Q., Zhao, M., Li, D., He, X., & Zang, W. (2023). Cholinergic drugs reduce metabolic inflammation and diabetic myocardial injury by regulating the gut bacterial component lipopolysaccharide‐induced ERK /Egr‐1 pathway. The FASEB Journal. https://doi.org/10.1096/fj.202202108r

Vancouver

Wu Q, Zhao M, Li D, He X, Zang W. Cholinergic drugs reduce metabolic inflammation and diabetic myocardial injury by regulating the gut bacterial component lipopolysaccharide‐induced ERK /Egr‐1 pathway. The FASEB Journal. 2023. doi:10.1096/fj.202202108r

BibTeX
@article{Wu2023,
  author = {Wu, Qing and Zhao, Ming and Li, Dongling and He, Xi and Zang, Weijin},
  title = {Cholinergic drugs reduce metabolic inflammation and diabetic myocardial injury by regulating the gut bacterial component lipopolysaccharide‐induced ERK /Egr‐1 pathway},
  journal = {The FASEB Journal},
  year = {2023},
  doi = {10.1096/fj.202202108r}
}
Kostenlos starten →